Skip to main content
Medical information Clinical review pending

Cytogenetics

Roma Risk of Ovarian Malignancy Algorithm Test

The Roma Risk of Ovarian Malignancy Algorithm Test assesses the likelihood of ovarian cancer in women by measuring CA125 and HE4 biomarkers. This test aids in early detection and informed decision-making for women with symptoms or risk factors.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
2 mL (1 mL minimum) serum collected in an SST tube.
Results
Confirm with the laboratory before booking. Sample collection on Monday or Thursday by 4 pm may allow for same-day reporting.
Preparation
Confirm with the laboratory before booking. Provide menopausal status at the time of sample collection.
Test priceKSh 9,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Roma Risk of Ovarian Malignancy Algorithm Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Women with symptoms suggestive of ovarian cancer (e.g., persistent bloating, abdominal pain, urinary changes)
  • ✓Women with a family history of ovarian or breast cancer
  • ✓Postmenopausal women with a pelvic mass
  • ✓Women aged 50 and above with relevant symptoms
  • ✓Women with a history of endometriosis and concerning symptoms
02

In plain language

What this test helps you understand

This test helps assess the risk of ovarian cancer, guiding further diagnostic steps and management decisions in women with symptoms or risk factors.
The Roma Risk of Ovarian Malignancy Algorithm Test is a diagnostic tool used to evaluate the risk of ovarian cancer in women. It is particularly useful for individuals who may have an increased risk due to factors like family history, age, or specific symptoms. This test helps healthcare providers determine the need for further investigation or management strategies.

The test measures the levels of two specific biomarkers, CA125 and HE4, in the blood. These levels are combined with the patient's menopausal status to calculate a risk score. This comprehensive approach provides a more accurate assessment of ovarian malignancy risk compared to using either biomarker alone.

This test is recommended for women experiencing symptoms suggestive of ovarian cancer or those with known risk factors. Early detection significantly improves outcomes for ovarian cancer, and this test can play a crucial role in identifying individuals who require further evaluation.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Provide menopausal status at the time of sample collection.
Sample2 mL (1 mL minimum) serum collected in an SST tube.
MethodologyImmunoassay for CA125 and HE4, combined with clinical information (menopausal status) using the Roma algorithm.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test is a risk assessment tool and does not provide a definitive diagnosis of ovarian cancer. Results should be interpreted by a healthcare professional in conjunction with clinical findings and other diagnostic tests. The accuracy may be affected by certain conditions or medications; confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test measures the levels of two biomarkers, CA125 and HE4, in your blood, along with your menopausal status, to calculate a risk score for ovarian cancer.
Women experiencing symptoms like persistent bloating or abdominal pain, those with a family history of ovarian or breast cancer, or postmenopausal women with a pelvic mass may be advised to take this test.
No, this test assesses the risk of ovarian cancer. A higher risk score indicates the need for further investigation by a healthcare professional, not a confirmed diagnosis.
Confirm preparation details with the laboratory before booking. It is important to provide your menopausal status when the sample is collected.
Results are typically reported as a risk score. Your doctor will interpret this score in the context of your symptoms and medical history to determine the next steps.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp